Yelin Lapidot Holdings Management Ltd. Has $14.09 Million Holdings in MediWound Ltd. $MDWD

Yelin Lapidot Holdings Management Ltd. trimmed its holdings in shares of MediWound Ltd. (NASDAQ:MDWD) by 5.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 763,069 shares of the biopharmaceutical company’s stock after selling 46,879 shares during the period. MediWound makes up about 2.8% of Yelin Lapidot Holdings Management Ltd.’s investment portfolio, making the stock its 9th biggest position. Yelin Lapidot Holdings Management Ltd. owned 0.06% of MediWound worth $14,086,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Meitav Investment House Ltd. lifted its holdings in shares of MediWound by 825.7% during the 3rd quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company’s stock worth $5,241,000 after acquiring an additional 260,116 shares during the period. Clal Insurance Enterprises Holdings Ltd bought a new position in shares of MediWound during the 3rd quarter worth about $1,042,000. Menora Mivtachim Holdings LTD. lifted its holdings in shares of MediWound by 348.8% during the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 78,539 shares of the biopharmaceutical company’s stock worth $1,415,000 after acquiring an additional 61,039 shares during the period. Rosalind Advisors Inc. lifted its holdings in shares of MediWound by 84.0% during the 3rd quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company’s stock worth $13,498,000 after acquiring an additional 341,993 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in shares of MediWound by 90.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 723 shares during the period. 46.83% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

MDWD has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research report on Tuesday, April 21st. Wall Street Zen cut shares of MediWound from a “hold” rating to a “strong sell” rating in a research report on Saturday, March 7th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $35.00.

MediWound Trading Up 3.4%

MDWD opened at $16.80 on Friday. The stock has a market capitalization of $215.88 million, a PE ratio of -8.00 and a beta of 0.21. MediWound Ltd. has a 1-year low of $14.90 and a 1-year high of $22.50. The firm has a 50-day moving average price of $16.88 and a two-hundred day moving average price of $17.60.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Saturday, February 14th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter. The company had revenue of $1.87 million during the quarter. MediWound had a negative net margin of 140.80% and a negative return on equity of 65.79%. On average, research analysts predict that MediWound Ltd. will post -2.75 EPS for the current year.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.